Integra LifeSciences (IART) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
BTIG Downgrades Integra LifeSciences (IART) to Sell
July 29, 2024 4:10 PM EDTBTIG analyst Ryan Zimmerman downgraded Integra LifeSciences (NASDAQ: IART) from Neutral to Sell with a price target of $22.00.
The analyst comments "We are downgrading to SELL following 2Q24 results, setting a $22 PT at 8.5x our 12-24 month EPS estimate. Another quarter and another negative update regarding IART's manufacturing and quality controls pushing out recovery to FY26. At the same time, IART's 2Q24 results were not bad. IART reported rev. of $418.2M (9.7%, 2.3% organic, 0.3% organic ex. Boston) and adj. EPS... More
